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Abstract
Primary lung lymphoma (PLL) is a rare unilateral or bilateral lung disorder that is challenging to diagnose solely based on clinical 
and radiological presentation. PLL may be misdiagnosed as pneumonia or a lung tumor due to non-specific findings. PLL is most 
frequently a mucosa-associated lymphoid tissue (MALT) lymphoma, a type of extranodal low-grade B-cell lymphoma most com-
monly discovered in the gastrointestinal tract. PLL should be considered in the differential diagnosis of non-resolving pneumonias. 
Herein we present a case of an 84-year-old patient discovered to have a primary pulmonary MALT lymphoma presenting as 
a non-resolving pneumonia causing a clinical challenge. 
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Introduction
Primary lung lymphoma (PLL) is a  rare di-
sease that encompasses many histologic types of 
lymphomas. It accounts for < 1% of all pulmona-
ry neoplasms and only 3–4% of all extranodal non
-Hodgkin’s lymphomas (NHLs) with a median age 
of diagnosis in the sixth decade of life [1, 2]. The 
most common histological type of PLL are those 
arising from mucosa-associated lymphoid tissue 
(MALT), which were first described by Isaacson 
and Wright in 1983 [2, 3]. Although MALT most 
frequently develops in the gastrointestinal tract, 
other sites can include the salivary glands, orbits, 
and lungs. MALT lymphoma may be associated 
with chronic inflammatory conditions and has 
been seen with chronic infections as well as au-
toimmune disorders e.g. Sjögren’s Syndrome [2]. 
PLL is often asymptomatic; however, patients may 
present with non-specific respiratory symptoms 
such as cough, shortness of breath, or constitu-
tional symptoms. Herein we describe a case of 
primary pulmonary MALT lymphoma presenting 
as a non-resolving pneumonia that caused a dia-
gnostic challenge. 
Case report 
An 84-year-old, African American, non-smo-
ker male with a history of hypertension (HTN) and 
benign prostatic hyperplasia (BPH) presented to 
his primary care physician with a two-week histo-
ry of non-productive cough. He denied chest pain 
or shortness of breath. The patient was treated 
for possible walking pneumonia on an outpatient 
basis with doxycycline without resolution of his 
symptoms. Patient was then referred to a pulmo-
nologist for further evaluation. He was retreated 
with levofloxacin and, again, failed to show 
improvement. He was then recommended for an 
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outpatient bronchoscopy to rule out other possi-
ble infectious or rheumatological etiology to his 
symptoms, but the patient refused. His symptoms 
continued to persist and worsen with significant 
weight loss of nine kilograms over the course of 
a year and a half. Due to worsening cough the 
patient was sent to the emergency room for ex-
peditious workup. Past medical history revealed 
a previous episode of pneumonia successfully 
treated with antibiotics approximately 18 months 
prior. The patient reported that he was a pharma-
cist, and denied a history of drug or alcohol use 
or exposure to any toxins. There was no known 
exposure to Mycobacterium tuberculosis or other 
communicable diseases. On examination, patient 
was afebrile with stable vital signs, blood pressu-
re (BP) of 137/77 mm Hg, heart rate (HR) of 66, 
oxygen saturation (O2sat) of 93%, respiratory rate 
(RR) of 16 breaths per minute and a temperature 
of 36.5 degrees Celsius. Initial laboratory findings 
and liver function tests have been summarized 
in Table 1. Lactose dehydrogenase was not me-
Table 1. Initial laboratory findings
WBC 7.35 ( 4.80–10.80 K/ul) 
RBC 4.46 (4.50–5.90M/ul)
HGB 12.5(13.5–17.5 g/dL)
HCT 38.2(42–52%)
PLT 398 (150–400 K/ul)
MCV 85.7 (80–100 fL) 
ESR 61 (0–25 mm)
Glucose 82 (74–99 mg/dL)
BUN 29.0 (8.0–23.0 mg/dL)
Creatinine 2.14 (0.70–1.20 mg/dL)
Sodium 134 (136–145 mmol/L)
Potassium 4.9 (3.5–5.1 mmol/L)
Chloride 98 (98–107 mmol/l)
Bicarbonate 24 (22–29 mmol/l)
Calcium 10.0 (8.6–10.4 mg/dL)
Liver function tests
Protein (total) 6.6 (6.4–8.3g/dl)
Albumin 3.8 (3.5 5.2 g/dl)
AST 17 (5–40 U/L)
ALT 16 (5–41U/L)
Alkaline phosphatase 81 (40–130 U/L)
Bilirubin (total) 0.5 (0.0–1.2 mg/dl)
Bilirubin (direct) 0.1 (0.0–0.9 mg/dl)
Bilirubin (indirect) 0.4 ( 0.0–0.9 mg/dl)
Figure 1. Chest X-ray Right upper and middle lobe scarring and ate-
lectasis with cystic changes. Possible raised right hemi-diaphragm
Figure 2. Non-contrast CT lung scan of chest Extensive right-sided 
airspace opacities with multiple cysts. No air bronchograms
asured. Physical exam was unremarkable except 
for bilateral rhonchi on auscultation. Chest X-ray 
(Fig. 1) showed features suggestive of scarring, 
atelectasis, and cystic changes in the right lung 
indicating possible bronchiectasis. Non-contrast 
chest CT (Fig. 2) showed a  right-sided pleural 
effusion and opacity with likely consolidation 
suspicious of pneumonia.
Sputum and serological testing was then per-
formed that was negative for bacteria and fungi. 
Screenings for atypical pneumonia microorga-
nisms were negative. Sputum acid-fast bacillus 
testing and QuantiFERON-TB Gold test were also 
both found to be negative. Due to non-resolving 
pneumonia and recent reported weight loss, sub-
sequent bronchoscopy was performed. Biopsies 
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with a MALT lymphoma in the right lung. The 
Ki-67 proliferative index is 10% - 15%. Anti-Pan 
Cytokeratin AE1/AE3 fluorophore highlights the 
focal LEL. 
After discovery of PLL further investigation 
for possible other MALT lesions was performed 
— ultrasound and computer tomography of the 
abdomen were unremarkable. Patient was re-
ferred to oncology due the extensiveness of the 
disease and surgery was ruled out. The patient 
was treated with a  chemotherapy regimen of 
cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) and rituximab. After 6 cycles 
of chemotherapy, positron emission tomography 
(PET) revealed the patient to be disease free and 
he was followed on an outpatient basis. 
Discussion
Primary lung lymphoma (PLL) is a rare uni-
lateral or bilateral lung disorder defined as clonal 
lymphoid proliferation affecting one or both lungs 
(parenchyma and/or bronchi) in a patient with 
no detectable extrapulmonary involvement at 
diagnosis or during the subsequent 3 months [4]. 
PLL is most frequently a  MALT lymphoma: 
a type of extranodal low-grade B-cell lymphoma 
characterized by proliferation of clonal marginal 
zone lymphocytes, which is most traditionally 
associated with Helicobacter Pylori found in the 
gastrointestinal tract, specifically the stomach [5]. 
MALT lymphomas (MALTomas) may also develop 
due to chronic inflammation or chronic autoim-
mune diseases e.g. Sjögren’s syndrome [2, 6]. 
PLL presents a clinical challenge, as physical or 
radiological presentation alone is often not eno-
ugh to make the diagnosis thus requiring a high 
index of suspicion, which may help to determine 
presence of this rare, indolent disease. PLL, due 
to its non-specific signs and symptoms may be 
misdiagnosed as pneumonia or a lung tumor. Here 
we have described a case of a MALT lymphoma 
located primarily in the lung masking itself as 
a non-resolving pneumonia. 
MALT lymphomas most commonly present 
non-specifically with 36-50% of patients being 
asymptomatic at the time of diagnosis [7, 8]. 58% 
of symptomatic patients most commonly reported 
symptoms of dry cough, dyspnea, chest pain, and 
hemoptysis; 22% of symptomatic patients report B 
type symptoms such as weight loss, fever, and night 
sweats [7, 9]. B type symptoms overlapped with 
respiratory manifestations creates a clinical conun-
drum as was seen in our patient. Initial diagnostic 
workup in such patients often includes laboratory 
Figure 3. Immunohistochemistry, CD20+, B-cell marker
Figure 4. Immunohistochemistry, Bcl-2+. B-cell marginal zone lym-
phoma marker
taken from the right upper and middle lobe sho-
wed MALT extranodal marginal zone lymphoma 
(MZL) of the bronchial submucosa heavily infil-
trated by small-to medium sized lymphoid cells 
containing round or oval nuclei with dispersed 
chromatin, inconspicuous nucleoli, and moderate 
amounts of cytoplasm. Lymphoepithelial lesion 
(LEL) was focally present, which is frequently 
associated with MALT lymphoma. 
Immunohistochemistry demonstrated neo-
plastic lymphocytes positive for CD20 (B-cell 
marker) (Fig. 3) and Bcl-2 (marginal zone lym-
phoma marker) (Fig. 4). Neoplastic lymphocytes 
were negative for Bcl-1 (mantle cell lymphoma 
marker), CD3 and CD5 (T-cell markers), CD10 
(acute lymphoblastic leukemia marker), CD23 
(IgE receptor antibody), CD43 (T-cell activation 
marker), and CD56 (natural killer cell marker). 
These results demonstrate that this patient’s 
diagnosis is a type 2 B-cell lymphoma, consistent 
Asma Iftikhar et al., Primary pulmonary MALT lymphoma presenting as non-resolving pneumonia
205www.journals.viamedica.pl
and diagnostic imaging if infectious etiology is 
suspected. Radiological examinations have shown 
that non specific patchy opacities or mass like con-
solidation are seen in up to 68% of patients [10]. 
The management algorithm of PLL typically 
follows that of newly discovered masses with 
the gold standard being biopsy of the suspicious 
mass. Sampling techniques include transthoracic 
needle biopsy, transbronchial biopsy, open thora-
cotomy and wedge resection by thoracotomy [11]. 
Our case highlights the use of transbronchial 
biopsy via bronchoscopy, which is conservative 
in the spectrum of tissue sampling procedures. 
Often diagnosis is more challenging and requires 
more invasive techniques as reported by Cordier 
et al. and Ferraro et al. in which 89% and 90% 
of patients required an open thoracotomy for 
definitive diagnosis of PLL [9, 12].
Supplemental diagnostic techniques such as 
bronchoalveolar lavage (BAL) may also be used to 
diagnose; however, BAL sensitivity for MALT lym-
phoma is only 66% [13]. Immunohistochemistry 
may also aid in the diagnosis to distinguish MALT 
lymphoma from other small B-cell non-Hodgkin’s 
lymphomas as it did in this case. B-cell-associated 
antigens such as CD19, CD20, CD22, and CD79a 
may be expressed in MALT lymphomas. 
Treatment options for primary lung MALT 
lymphoma treatment are either surgical resection 
or chemotherapy regimen of CHOP with rituxi-
mab. Surgical intervention with adjuvant che-
motherapy is preferred to preserve lung function 
[14]. However, PLL is an indolent disease that does 
not always require immediate intervention. Most 
patients show no growth or spread of lymphoma 
for up to 12 months after diagnosis, and have 
a median time to progression of 5.6 years [15]. 
Even without treatment patients have favorable 
prognosis. The ten-year survival for MZL is 53% 
[12] with no difference in survival rates of uni-
lateral versus bilateral disease [10].
Conclusion
Primary lung lymphomas are a  rare occu-
rrence that are difficult to diagnose. They are 
usually asymptomatic with non-specific clinical 
manifestations or radiological characteristics. 
Non-specific symptoms may lead to difficulty in 
diagnosis. Definitive diagnosis of PLL as a MALT 
lymphoma is based on histological examination 
of surgical tissue biopsies. Treatment options 
for patients like the one presented here could 
include monitoring progression, surgery, che-
motherapy or radiotherapy. There is no current 
established management protocol. Treatment is 
instead guided by expert opinion rather than 
evidence based medicine from randomized cli-
nical trials. If clinical suspicion is high, a  full 
diagnostic workup — possibly including inva-
sive tissue sampling procedures — should be 
considered to accurately diagnose PLL patients 
as early as possible.
Conflict of interest
The authors declare no conflict of interest.
References:
1. Miller DL, Allen MS. Rare pulmonary neoplasms. Mayo Clin 
Proc. 1993; 68(5): 492–498, indexed in Pubmed: 8386792.
2. Cadranel J, Wislez M, Antoine M, et al. AIDS-related prima-
ry pulmonary lymphoma. Am J Respir Crit Care Med. 1998; 
158(4): 1221–1229, doi: 10.1164/ajrccm.158.4.9801057, in-
dexed in Pubmed: 9769285.
3. Isaacson P, Wright DH. Malignant lymphoma of mucosa-asso-
ciated lymphoid tissue. A distinctive type of B-cell lymphoma. 
Cancer. 1983; 52(8): 1410–1416, indexed in Pubmed: 6193858.
4. Majid N, Kamal ElB, Oncology B, et al. Primary pulmonary 
lymphoma: About five cases and literature review. Lung India. 
2014; 31(1): 53–55, doi: 10.4103/0970-2113.125909, indexed 
in Pubmed: 24669084.
5. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori 
infection and gastric lymphoma. N Engl J Med. 1994; 330(18): 
1267–1271, doi: 10.1056/NEJM199405053301803, indexed in 
Pubmed: 8145781.
6. Isaacson PG. Mucosa-associated lymphoid tissue lymphoma. 
Semin Hematol. . 1999; 36(2): 139–147.
7. Borie R, Wislez M, Thabut G, et al. Clinical characteristics and 
prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 
2009; 34(6): 1408–1416, doi: 10.1183/09031936.00039309, in-
dexed in Pubmed: 19541720.
8. Kurtin PJ, Myers JL, Adlakha H, et al. Pathologic and clinical 
features of primary pulmonary extranodal marginal zone B-
cell lymphoma of MALT type. Am J Surg Pathol. 2001; 25(8): 
997–1008, indexed in Pubmed: 11474283.
9. Cordier JF, Chailleux E, Lauque D, et al. Primary pulmonary 
lymphomas. A clinical study of 70 cases in nonimmunocom-
promised patients. Chest. 1993; 103(1): 201–208, indexed in 
Pubmed: 8417879.
10. Parissis H. Forty years literature review of primary lung lym-
phoma. J Cardiothorac Surg. 2011; 6: 23, doi: 10.1186/1749-
8090-6-23, indexed in Pubmed: 21371331.
11. Wannesson L, Cavalli F, Zucca E. Primary pulmonary lym-
phoma: current status. Clin Lymphoma Myeloma. 2005; 6(3): 
220–227, doi: 10.3816/CLM.2005.n.049, indexed in Pubmed: 
16354327.
12. Ferraro P, Trastek VF, Adlakha H, et al. Primary non-Hodg-
kin’s lymphoma of the lung. Ann Thorac Surg. 2000; 69(4): 
993–997, indexed in Pubmed: 10800781.
13. Poletti V, Romagna M, Gasponi A, et al. Bronchoalveolar lavage 
in the diagnosis of low-grade, MALT type, B-cell lymphoma 
in the lung. Monaldi Arch Chest Dis. 1995; 50(3): 191–194, 
indexed in Pubmed: 7663488.
14. Lee S, Kim MJ, Kim JS, et al. Consortium for Improving Survi-
val of Lymphoma (CISL) study group. Phase II study of gemci-
tabine for treatment of patients with advanced stage marginal 
zone B-cell lymphoma: Consortium for Improving Survival 
of Lymphoma (CISL) trial. Invest New Drugs. 2010; 28(2): 
171–177, doi: 10.1007/s10637-009-9260-6, indexed in Pubmed: 
19421710.
15. Troch M, Streubel B, Petkov V, et al. Does MALT lymphoma of 
the lung require immediate treatment? An analysis of 11 un-
treated cases with long-term follow-up. Anticancer Res. 2007; 
27(5B): 3633–3637, indexed in Pubmed: 17972528.
